Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

JP Morgan Downgrades 10x Genomics to Neutral, Lowers Price Target to $20

Author: Benzinga Newsdesk | July 18, 2024 08:18am

JP Morgan analyst Rachel Vatnsdal downgrades 10x Genomics (NASDAQ:TXG) from Overweight to Neutral and lowers the price target from $40 to $20.

Posted In: TXG